BACKGROUND: Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency characterized by recurrent respiratory tract infections, mainly sustained by encapsulated bacteria, that may cause irreversible changes in the lungs. METHODS: Forty patients with CVID were evaluated by computed tomography of the lung; 20 of these underwent computed tomographic follow-up in a 5-year period, during which immunoglobulin replacement therapy was regularly performed. RESULTS: Pulmonary changes were present in 65% of patients; bronchiectases were present in 65.38%. The incidence of pulmonary nodules was very high (38.46%) and correlated with splenomegaly (70%) and autoimmune phenomena (80%). CONCLUSIONS: Our study underscores the essential role of imaging, in particular computed tomography, in the identification and monitoring of pulmonary lesions in a large cohort of CVID patients, contributing at the same time to select patients more at risk to develop nodular lesions and potentially to use more appropriate therapeutic strategies.
BACKGROUND: Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency characterized by recurrent respiratory tract infections, mainly sustained by encapsulated bacteria, that may cause irreversible changes in the lungs. METHODS: Forty patients with CVID were evaluated by computed tomography of the lung; 20 of these underwent computed tomographic follow-up in a 5-year period, during which immunoglobulin replacement therapy was regularly performed. RESULTS: Pulmonary changes were present in 65% of patients; bronchiectases were present in 65.38%. The incidence of pulmonary nodules was very high (38.46%) and correlated with splenomegaly (70%) and autoimmune phenomena (80%). CONCLUSIONS: Our study underscores the essential role of imaging, in particular computed tomography, in the identification and monitoring of pulmonary lesions in a large cohort of CVIDpatients, contributing at the same time to select patients more at risk to develop nodular lesions and potentially to use more appropriate therapeutic strategies.
Authors: A A J M van de Ven; P A de Jong; D P Hoytema van Konijnenburg; O A M Kessels; M Boes; E A M Sanders; S W J Terheggen-Lagro; J M van Montfrans Journal: Clin Exp Immunol Date: 2011-06-02 Impact factor: 4.330
Authors: Maria Pia Bondioni; Vassilios Lougaris; Giuseppe Di Gaetano; Tiziana Lorenzini; Annarosa Soresina; Francesco Laffranchi; Diego Gatta; Alessandro Plebani Journal: J Clin Immunol Date: 2016-10-21 Impact factor: 8.317
Authors: Katharina Schütz; Diana Alecsandru; Bodo Grimbacher; Jamanda Haddock; Annemarie Bruining; Gertjan Driessen; Esther de Vries; Peter M van Hagen; Ieneke Hartmann; Francesco Fraioli; Cinzia Milito; Milica Mitrevski; Isabella Quinti; Goffredo Serra; Peter Kelleher; Michael Loebinger; Jiri Litzman; Vera Postranecka; Vojtech Thon; Judith Babar; Alison M Condliffe; Andrew Exley; Dinakantha Kumararatne; Nick Screaton; Alison Jones; Maria P Bondioni; Vassilios Lougaris; Alessandro Plebani; Annarosa Soresina; Cesare Sirignano; Giuseppe Spadaro; Nermeen Galal; Luis I Gonzalez-Granado; Sabine Dettmer; Robert Stirling; Helen Chapel; Mary Lucas; Smita Patel; Claire-Michele Farber; Isabelle Meyts; Arpan K Banerjee; Scott Hackett; John R Hurst; Klaus Warnatz; Benjamin Gathmann; Ulrich Baumann Journal: J Clin Immunol Date: 2018-12-13 Impact factor: 8.317
Authors: Paul J Maglione; Jessica R Overbey; Lin Radigan; Emilia Bagiella; Charlotte Cunningham-Rundles Journal: Ann Allergy Asthma Immunol Date: 2014-05-29 Impact factor: 6.347
Authors: Paul J Maglione; Huaibin M Ko; Mary B Beasley; James A Strauchen; Charlotte Cunningham-Rundles Journal: J Allergy Clin Immunol Date: 2013-10-13 Impact factor: 10.793